BioMarin Announces $5.2B Amicus Acquisition Financing with $3.65B New Debt, Reports Preliminary 2025 Results

summarizeSummary

BioMarin Pharmaceutical Inc. announced a substantial debt financing package totaling $3.65 billion to fund its pending $5.2 billion acquisition of Amicus Therapeutics, alongside preliminary full-year 2025 financial results.

check_boxKey Events

• Amicus Therapeutics Acquisition Financing

  BioMarin is raising $3.65 billion in new debt, including $850 million in senior unsecured notes and $2.8 billion in term loans, to fund the approximately $5.2 billion cash acquisition of Amicus Therapeutics.

• Significant Debt Increase

  The new debt facilities represent a substantial increase in leverage for BioMarin, with proceeds primarily dedicated to the acquisition consideration and related expenses.

• Preliminary 2025 Financials Updated

  The company reported preliminary unaudited full-year 2025 total revenues of approximately $3.2 billion, including $920 million from VOXZOGO sales, and $2.1 billion in cash and investments, providing more detail than the prior 8-K on January 12, 2026.

• Pro Forma Financial Impact

  Unaudited pro forma financial information for the combined entity shows a net loss for the year ended December 31, 2024, and the nine months ended September 30, 2025, indicating potential short-term financial headwinds post-acquisition.

auto_awesomeAnalysis

This filing details BioMarin's strategy to finance its transformational $5.2 billion acquisition of Amicus Therapeutics, representing nearly 50% of BioMarin's current market capitalization. The company plans to issue $850 million in senior unsecured notes and secure $2.8 billion in new term loans, significantly increasing its debt burden. While the acquisition aims to expand BioMarin's portfolio, the pro forma financial information indicates a net loss for the combined entity in prior periods, and the filing highlights substantial integration risks. Investors should closely monitor the closing of the acquisition, the successful integration of Amicus, and the impact of the increased leverage on BioMarin's future profitability and financial health.